10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding

10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding

Upper gastrointestinal (GI) disorders encompass a spectrum of highly prevalent luminal conditions ranging from benign, symptomatic gastroesophageal reflux disease (GERD) to life-threatening peptic ulcer perforation and acute variceal hemorrhage. In Canadian pharmacy practice, managing these conditions requires an in-depth understanding of gastric acid secretory physiology, the mucosal defense barrier, the pharmacology and safety of acid-suppressive therapies, evidence-based antimicrobial regimens for Helicobacter pylori, and emergency pharmacotherapeutic resuscitation protocols.

---

Gastroesophageal Reflux Disease (GERD): Clinical Assessment & Triage

GERD develops when retrograde flow of gastric contents into the esophagus causes troublesome symptoms or mucosal complications (erosive esophagitis, peptic stricture, Barrett's esophagus, esophageal adenocarcinoma). The primary pathophysiology involves incompetence of the lower esophageal sphincter (LES), transient lower esophageal sphincter relaxations (TLESRs), anatomical hiatal hernia, delayed gastric emptying, and compromised esophageal peristaltic clearance.

Clinical Presentation: Typical vs. Atypical Symptoms

• Typical Esophageal Symptoms: Pyrosis (heartburn)—a retrosternal burning sensation radiating upward toward the neck—and acid regurgitation (effortless reflux of sour or bitter gastric juice into the pharynx or mouth). Water brash (sudden hypersalivation provoked by an esophageal-salivary reflex) is also classic.
• Atypical (Extra-Esophageal) Manifestations: Chronic dry cough, asthma-like wheezing, hoarseness, chronic laryngitis, globus sensation ("lump in the throat"), and dental enamel erosions.

                               GERD & DYSPEPSIA CLINICAL TRIAGE
                               
                     Patient Presenting with Heartburn, Dyspepsia, or Regurgitation
                                                  │
                                     SCREEN FOR ALARM FEATURES
                     ┌────────────────────────────────────────────────────────────┐
                     │ • Dysphagia (Difficulty swallowing)                        │
                     │ • Odynophagia (Painful swallowing)                         │
                     │ • Involuntary, unexplained weight loss                     │
                     │ • Overt GI bleeding (Hematemesis, melena) or occult blood  │
                     │ • Unexplained iron deficiency anemia                       │
                     │ • Persistent, refractory vomiting (> 7-14 days)            │
                     │ • Age ≥ 60 with new dyspepsia (CAG/ACG 2017 guideline)     │
                     │ • Palpable epigastric mass or family history of GI cancer │
                     └────────────────────────────────────────────────────────────┘
                                                  │
                         ┌────────────────────────┴────────────────────────┐
                         ▼                                                 ▼
                ALARM FEATURES PRESENT?                           NO ALARM FEATURES
                         │                                                 │
                         ▼                                                 ▼
           URGENT UPPER ENDOSCOPY (EGD)                           EMPIRIC MANAGEMENT
           Rule out malignancy, stricture,                   • Lifestyle & dietary modifications
           Barrett's esophagus, severe ulcer                 • 4-8 week trial of once-daily PPI
                                                             • Evaluate response & deprescribe

Non-Pharmacological Lifestyle Modifications

Evidence-based lifestyle interventions with demonstrated clinical efficacy in reducing nocturnal and postprandial reflux include:

1. Head of Bed Elevation: Elevate the head of the bed by 15 to 20 cm (6 to 8 inches) using bed risers under the bedposts or a high-density foam sleeping wedge. (Using extra pillows merely bends the neck, increasing intra-abdominal pressure without elevating the esophagus).
2. Avoid Late Meals: Restrict all caloric and beverage intake for at least 2 to 3 hours prior to recumbency or bedtime.
3. Weight Loss: In overweight or obese individuals ($BMI \ge 25$ kg/m²), weight reduction significantly decreases intra-abdominal pressure and TLESR frequency.
4. Dietary Adjustments: Selective avoidance of foods that lower LES basal tone or irritate esophageal mucosa (chocolate, high-fat meals, caffeine, peppermint, citrus fruits, tomato-based foods, alcohol) if the patient recognizes them as specific symptom triggers.

---

Pharmacotherapy of GERD: Antacids, H2RAs, and Proton Pump Inhibitors

                                GASTRIC ACID SUPPRESSION SPECTRUM
                                
  Antacids / Alginates (Gaviscon) ──> Rapid Onset (< 15 min), Short Duration (1-2 h), PRN breakthrough
  H2-Receptor Antagonists (Famotidine) ──> Intermediate Onset (1 h), Duration 8-12 h, Rapid Tachyphylaxis (1-2 wks)
  Proton Pump Inhibitors (PPIs) ──> Delayed Onset (days for max), Irreversible H+/K+ ATPase, 24 h suppression

1. Antacids & Alginates

• Antacids (aluminum hydroxide, magnesium hydroxide, calcium carbonate): Chemically neutralize existing gastric hydrochloric acid, raising gastric pH above 3.5. Onset is rapid (5–15 minutes), but duration is brief (30–60 minutes on an empty stomach; up to 2 hours when taken after meals).
• Alginate Formulations (Gaviscon): In the presence of gastric acid, alginic acid precipitates into a viscous, frothy carboxymethylcellulose "raft" that floats on the surface of the gastric contents (the "acid pocket"), acting as a mechanical physical barrier against esophageal reflux.

2. Histamine-2 Receptor Antagonists (H2RAs)

• Agents: Famotidine (10–20 mg PO daily to BID), Nizatidine.
• Mechanism: Reversible competitive antagonists of histamine at $H_2$ receptors on parietal cell basolateral membranes, blocking histamine-stimulated gastric acid secretion.
• Clinical Role & Limitation: Useful for mild, intermittent GERD or nocturnal acid breakthrough. However, daily continuous use leads to rapid tachyphylaxis (tolerance) within 7 to 14 days due to upregulation of gastrin and neural pathways, significantly diminishing their therapeutic efficacy.

3. Proton Pump Inhibitors (PPIs) — Foundational Therapy

• Agents: Omeprazole (20 mg), Pantoprazole (40 mg), Lansoprazole (30 mg), Esomeprazole (20–40 mg), Rabeprazole (20 mg).
• Mechanism of Action: PPIs are prodrugs that are absorbed into the systemic circulation and diffuse into the acidic secretory canaliculi of gastric parietal cells. In this low pH environment ($pH < 2$), they become protonated into active sulfenamide intermediates, which form irreversible covalent disulfide bonds with cysteine residues on the active $H^+/K^+$-ATPase enzyme pump (the final common pathway of acid secretion), completely inactivating the pump.
• Administration Timing Nuance: Because PPIs only bind to actively translocated, secreting proton pumps, they must be ingested 30 to 60 minutes before the first meal of the day (or 30–60 minutes before the morning and evening meals if BID dosing is prescribed). Ingesting a PPI at bedtime or without a subsequent meal diminishes acid-suppressive efficacy by over 50%.
• CYP2C19 Interactions: Omeprazole and esomeprazole moderately inhibit CYP2C19, potentially diminishing the bioactivation of clopidogrel (a prodrug dependent on CYP2C19 for conversion to its active antiplatelet metabolite). While the clinical significance remains debated, pantoprazole has the lowest affinity for CYP2C19 and is the preferred PPI for patients co-prescribed clopidogrel.

4. Long-Term PPI Safety Concerns & Monitoring

5. Structured PPI Deprescribing Protocols

Because up to 50% of patients receiving long-term PPI therapy lack a valid clinical indication, Choosing Wisely Canada and evidence-based deprescribing guidelines recommend periodic re-evaluation. Patients with uncomplicated GERD who have completed an 4- to 8-week course and achieved symptom resolution should undergo a trial of deprescribing:

• Tapering Strategy: Reduce daily dose by 50% (e.g., from 40 mg to 20 mg daily) for 2 to 4 weeks, or switch to alternate-day dosing, or transition to on-demand (PRN) therapy or a low-dose H2RA.
• Rebound Acid Hypersecretion: Abrupt discontinuation of chronic PPI therapy triggers rebound acid hypersecretion secondary to hypergastrinemia (chronic acid suppression stimulates antral G-cells to hypersecrete gastrin, causing parietal cell hyperplasia). Upon sudden withdrawal, hyperplastic parietal cells produce massive acid rebound lasting 2 to 4 weeks. Pharmacists must counsel patients that mild transient heartburn during tapering does not necessarily signify GERD recurrence and can be managed with antacids or alginates.

---

Peptic Ulcer Disease (PUD): Pathogenesis & Differential Diagnosis

Peptic ulcer disease refers to mucosal defects extending through the muscularis mucosae into the deeper layers of the stomach or duodenum. PUD results from an imbalance between aggressive luminal factors (gastric acid, pepsin, bile salts) and mucosal protective defense mechanisms (gastric mucus-bicarbonate barrier, mucosal blood flow, epithelial cell restitution, endogenous prostaglandins $PGE_2$ and $PGI_2$).

Duodenal Ulcers vs. Gastric Ulcers

---

Helicobacter pylori Infection: Diagnostic Modalities & Canadian Eradication

Helicobacter pylori is a microaerophilic, spiral, Gram-negative bacterium that colonizes the gastric mucosa. It produces high levels of urease, which hydrolyzes urea into ammonia and carbon dioxide ($CO_2$), buffering ambient gastric acid and allowing the organism to survive in the hostile gastric lumen while eliciting chronic active gastritis.

Diagnostic Modalities & The "Washout Rule"

• Urea Breath Test (13C or 14C UBT): The gold-standard non-invasive test for active infection. The patient ingests radiolabeled urea; bacterial urease cleaves urea, and labeled $CO_2$ is measured in exhaled breath. High sensitivity and specificity (> 95%).
• Stool Antigen Test (SAT): Detects H. pylori antigens in feces via monoclonal antibody immunoassay. Reliable alternative to UBT.
• Serology (Serum IgG): Detects past systemic antibody exposure. Serology is obsolete and clinically unhelpful because antibodies persist for years after successful eradication; it cannot distinguish between active infection and resolved past infection.

The Toronto Consensus Canadian Eradication Regimens

Historically, standard triple therapy (PPI + clarithromycin + amoxicillin) was the first-line standard. Clarithromycin resistance has risen in Canada and in many regions now exceeds 15%. The Toronto Consensus (2016) therefore recommends two equal first-line quadruple regimens, each for 14 days: bismuth quadruple therapy (PBMT) and non-bismuth concomitant therapy (PAMC). It restricts PPI triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) to areas with documented clarithromycin resistance below 15% or proven local eradication rates above 85%. Sequential therapy is not recommended.

                         TORONTO CONSENSUS FIRST-LINE ERADICATION REGIMENS
                         
                      Patient Diagnosed with Active H. pylori Infection
                                              │
                     ┌────────────────────────┴────────────────────────┐
                     ▼                                                 ▼
       FIRST-LINE OPTION 1 (PBMT)                            FIRST-LINE OPTION 2 (PAMC)
       14-Day Bismuth Quadruple Therapy                      14-Day Non-Bismuth Quadruple
                     │                                       (Concomitant Therapy)
                     ▼                                                 │
      ┌─────────────────────────────┐                                  ▼
      │ • PPI (Standard dose BID)   │                   ┌─────────────────────────────┐
      │ • Bismuth subsalicylate     │                   │ • PPI (Standard dose BID)   │
      │   524 mg PO QID             │                   │ • Amoxicillin 1000 mg BID   │
      │ • Metronidazole 500 mg TID  │                   │ • Metronidazole 500 mg BID  │
      │ • Tetracycline 500 mg QID   │                   │ • Clarithromycin 500 mg BID │
      └─────────────────────────────┘                   └─────────────────────────────┘
                     │                                                 │
                     └────────────────────────┬────────────────────────┘
                                              │
                                     Mandatory Washout Gate
                               • Stop Antibiotics/Bismuth ≥ 4 weeks
                               • Stop PPI ≥ 2 weeks
                                              │
                                              ▼
                                  CONFIRMATION OF ERADICATION
                               (Test of Cure via UBT or Stool Antigen)

Detailed Regimen Breakdown

1. Bismuth Quadruple Therapy (PBMT, First-Line) — Duration: 14 Days:
   • PPI: Standard dose PO BID (e.g., pantoprazole 40 mg BID, omeprazole 20 mg BID, or esomeprazole 20 mg BID) taken 30–60 min before breakfast and dinner.
   • Bismuth subsalicylate: 524 mg (two 262 mg chewable tablets) PO QID (with meals and at bedtime).
   • Metronidazole: 500 mg PO TID or QID (or 250 mg QID).
   • Tetracycline HCl: 500 mg PO QID.
   • Counseling Pearls: Bismuth causes harmless, temporary dark-black discoloration of the stool and tongue. Metronidazole can cause a disulfiram-like reaction with alcohol and a metallic taste. Tetracycline causes photosensitivity, binds multivalent cations (calcium, dairy, iron, antacids), and is strictly contraindicated in pregnancy and children < 8 years.
2. Non-Bismuth Quadruple Therapy (Concomitant Therapy, PAMC, First-Line) — Duration: 14 Days:
   • PPI: Standard dose PO BID.
   • Amoxicillin: 1000 mg PO BID.
   • Metronidazole: 500 mg PO BID.
   • Clarithromycin: 500 mg PO BID.
   • Clinical Note: The Toronto Consensus recommends PAMC as a first-line option equal to PBMT; it is convenient (BID) but uses three antibiotics. The < 15% clarithromycin-resistance restriction applies to triple PPI-clarithromycin therapy, not to concomitant therapy. Choose PBMT if the patient has had a macrolide before or has a penicillin allergy.
3. Test of Cure (Mandatory Confirmation):
   • Eradication must be objectively confirmed in all treated patients using a Urea Breath Test or Stool Antigen Test performed at least 4 weeks after completing antibiotic therapy and at least 2 weeks after discontinuing PPI therapy.

---

NSAID-Induced Ulcers & Gastroprotection Strategies

Non-steroidal anti-inflammatory drugs (NSAIDs) cause gastric mucosal injury through dual mechanisms: direct topical epithelial irritation and, predominantly, systemic inhibition of cyclooxygenase-1 (COX-1). COX-1 is constitutively expressed in gastric mucosal cells, synthesizing protective prostaglandins ($PGE_2$ and $PGI_2$) that stimulate gastric mucus and bicarbonate secretion, maintain mucosal blood flow, and inhibit basal parietal acid secretion.

GI Risk Stratification & Gastroprotective Interventions

                                NSAID GASTROPROTECTION MATRIX
                                
  HIGH GI RISK                                  MODERATE GI RISK                LOW GI RISK
  • Prior complicated ulcer (perforation, bleed) • Age ≥ 65 years               • No risk factors
  • Multiple moderate risk factors               • High-dose NSAID therapy      
  • Concurrent anticoagulant or antiplatelet     • Concurrent oral steroid      
                 │                               • Uncomplicated ulcer history  
                 ▼                                              │                              │
        AVOID NSAID IF POSSIBLE                                 ▼                              ▼
        If mandatory:                               Choose ONE:                     Standard NSAID alone
        • Celecoxib PLUS Daily PPI                  • Celecoxib alone OR            without PPI
                                                    • Traditional NSAID + Daily PPI

Clinical Nuances of Gastroprotective Agents:

• Proton Pump Inhibitors: Co-prescribing a daily PPI (e.g., pantoprazole 20–40 mg daily) is the primary first-line gastroprotective standard in Canada for moderate-to-high risk patients requiring NSAIDs.
• Misoprostol (Cytotec 200 mcg PO QID with meals): Synthetic prostaglandin $E_1$ analog that directly replaces deficient mucosal prostaglandins. Highly effective at preventing both gastric and duodenal ulcers, but severely limited by dose-dependent diarrhea (15%–30%) and abdominal cramping. Strictly contraindicated in pregnancy due to potent abortifacient actions and stimulation of uterine contractions.
• Selective COX-2 Inhibitors (Celecoxib): Spares mucosal COX-1 prostaglandins, reducing endoscopic ulcer rates by 50% compared to non-selective NSAIDs. However, when combined with low-dose aspirin, the GI safety advantage of celecoxib is completely abolished, necessitating co-prescribed PPI protection.
• Cardiovascular Safety Balance: All NSAIDs (selective and non-selective) increase the risk of myocardial infarction, stroke, and heart failure exacerbation by inhibiting vascular COX-2-derived prostacyclin ($PGI_2$). Naproxen (up to 500 mg BID) exhibits the most neutral cardiovascular risk profile, but carries high gastrointestinal toxicity, requiring mandatory daily PPI co-prescription in vulnerable patients.

---

Acute Upper Gastrointestinal Bleeding (UGIB): Emergency Resuscitation & Pharmacotherapy

Acute upper GI bleeding (bleeding originating proximal to the ligament of Treitz) represents a medical emergency with an overall mortality rate of 5% to 10%. Major etiologies include peptic ulcer bleeding (50%), esophageal or gastric varices (15%–20%), Mallory-Weiss tears (5%–10%), and erosive esophagitis/gastritis.

Clinical Resuscitation & Transfusion Strategy

1. Hemodynamic Stabilization: Secure airway, breathing, and circulation (ABCs); establish two large-bore peripheral IV lines (16- or 18-gauge); administer IV isotonic crystalloids (normal saline or Ringer's lactate) to restore end-organ perfusion.
2. Restrictive Red Blood Cell Transfusion Strategy:
   • In hemodynamically stable patients without acute myocardial ischemia, Canadian clinical practice guidelines mandate a restrictive transfusion threshold: transfuse packed red blood cells (pRBCs) when hemoglobin falls below < 70 g/L, targeting a post-transfusion hemoglobin of 70 to 80 g/L.
   • Landmark randomized trials (Villanueva et al.) proved that a restrictive transfusion strategy significantly reduces rebleeding and all-cause mortality compared to a liberal strategy (transfusing at Hb < 90 g/L). Liberal transfusion increases central venous pressure and portal venous pressures, blowing off immature hemostatic fibrin plugs.
   • Exception: In patients with active acute coronary syndromes or ongoing cardiovascular ischemia, maintain hemoglobin ≥ 90 to 100 g/L.

                          ACUTE UPPER GI BLEEDING RESUSCITATION BUNDLE
                          
                       Patient with Hematemesis, Melena, Coffee-Ground Emesis
                                                  │
                                     ABC RESUSCITATION & ACCESS
                                 Two Large-Bore IVs; Fluid resuscitation
                                 Restrictive RBC Transfusion (Target Hb 70-80 g/L)
                                                  │
                         ┌────────────────────────┴────────────────────────┐
                         ▼                                                 ▼
           NON-VARICEAL BLEEDING SUSPECTED                   SUSPECTED CIRRHOSIS / VARICEAL
           (Peptic Ulcer, NSAID use)                         (Stigmata of chronic liver disease)
                         │                                                 │
                         ▼                                                 ▼
           HIGH-DOSE INTRAVENOUS PPI                         VASOACTIVE THERAPY
           • Pantoprazole 80 mg IV bolus,                    • Octreotide 50 mcg IV bolus,
             then 8 mg/hr infusion x 72 h                      then 50 mcg/hr infusion x 2-5 days
           • (Or 40-80 mg IV BID intermittent)                                 │
                         │                                                 ▼
                         │                                   PROPHYLACTIC ANTIBIOTICS
                         │                                   • Ceftriaxone 1 g IV daily x 5-7 days
                         │                                     (Reduces SBP, rebleeding & death)
                         └────────────────────────┬────────────────────────┘
                                                  │
                                                  ▼
                                     PRE-ENDOSCOPY PROKINETIC
                                     • Erythromycin 250 mg IV 30-90 min pre-EGD
                                       (Clears gastric blood; improves visualization)
                                                  │
                                                  ▼
                                     EARLY ENDOSCOPY (Within 24 Hours)
                                     Endoscopic Hemostasis (Clips, Thermal, Banding)

Pharmacotherapy for Non-Variceal Upper GI Bleeding

1. High-Dose Intravenous PPI:
   • Regimen: Pantoprazole 80 mg IV bolus, followed by 8 mg/hour continuous IV infusion for 72 hours post-endoscopic hemostasis, OR high-dose intermittent IV PPI (e.g., pantoprazole 40–80 mg IV BID). Multiple meta-analyses and Canadian guidelines confirm that high-dose intermittent IV PPI is clinically non-inferior to continuous infusion in preventing rebleeding, surgical intervention, and mortality.
   • Pharmacodynamic Rationale: Normal blood clotting and platelet aggregation are profoundly impaired at acidic pH. At $pH < 5.4$, platelet aggregation is completely abolished, and pepsinogen is activated into pepsin, which actively dissolves fresh fibrin clots over the crater of the ulcer. Sustaining an intragastric pH > 6.0 stabilizes the platelet-fibrin hemostatic plug, preventing clot lysis and recurrent hemorrhage.
2. Pre-Endoscopic Prokinetic Agent (Erythromycin):
   • Regimen: Erythromycin 250 mg IV infused over 30 to 60 minutes, administered 30 to 90 minutes prior to endoscopy.
   • Mechanism: Erythromycin is a motilin receptor agonist that stimulates migrating motor complexes and accelerates gastric emptying. It clears fresh blood, clots, and retained debris from the gastric fundus, significantly improving endoscopic visualization, shortening procedure duration, and reducing the requirement for a second-look endoscopy.

Pharmacotherapy for Variceal Upper GI Bleeding

In patients with known cirrhosis, alcohol dependence, chronic hepatitis, or physical stigmata of chronic liver disease (spider nevi, ascites, caput medusae, jaundice):

1. Vasoactive Splanchnic Vasoconstrictor (Octreotide):
   • Regimen: Octreotide 50 mcg IV bolus, followed immediately by 50 mcg/hour continuous IV infusion for 2 to 5 days.
   • Mechanism: Octreotide is a synthetic somatostatin analog that inhibits the release of endogenous vasodilatory peptides (primarily glucagon). This causes selective splanchnic arterial vasoconstriction, decreasing splanchnic blood flow, portal venous inflow, and portal pressures, thereby arresting acute variceal bleeding.
2. Prophylactic Antibiotic Therapy:
   • Regimen: Ceftriaxone 1 g IV once daily for 5 to 7 days (or oral ciprofloxacin where local resistance is low).
   • Rationale: Bacterial infections occur in up to 50% of cirrhotic patients presenting with upper GI bleeding. Bacterial endotoxins stimulate endothelin release and worsen portal hypertension. Routine short-term prophylactic antibiotic therapy statistically reduces the incidence of spontaneous bacterial peritonitis (SBP), recurrent variceal hemorrhage, and all-cause mortality.
3. Secondary Prevention of Variceal Hemorrhage:
   • Following stabilization and endoscopic band ligation (EBL), patients must be initiated on non-selective beta-blockers (NSBBs: nadolol 40 mg daily, propranolol 20–40 mg BID, or carvedilol 6.25–12.5 mg daily) titrated to a resting heart rate of 55–60 bpm, in combination with serial band ligation until varices are completely obliterated.

---

Clinical Case Vignette: H. pylori Eradication & Upper GI Hemorrhage

A 54-year-old male business executive presents to the emergency department with a 12-hour history of passing voluminous, tarry black stools (melena) and feeling severely lightheaded upon standing. He has a 3-month history of burning epigastric discomfort that typically woke him around 2 AM and was temporarily relieved by drinking milk.

Clinical Assessment:

• Vital Signs: Blood pressure 104/64 mmHg (drops to 88/50 mmHg upon sitting; orthostatic hypotension), heart rate 116 bpm, respiratory rate 18 breaths/min, $SaO_2$ 98% on room air.
• Laboratory Results: Hemoglobin 76 g/L (baseline 145 g/L), platelets $260 \times 10^9/L$, INR 1.0, serum creatinine 92 µmol/L, BUN 12.4 mmol/L (elevated BUN/creatinine ratio reflects upper GI digestion and resorption of blood proteins).
• Medication History: Takes ibuprofen 400 mg PRN for headaches twice weekly. Has no known liver disease or history of heavy alcohol use.

Emergency Management & Hospital Course:

1. Initial Resuscitation: Two 16-gauge IV lines placed; 1000 mL normal saline infused over 45 minutes, normalizing heart rate to 88 bpm. In accordance with restrictive transfusion guidelines, pRBC transfusion is withheld because hemoglobin is 76 g/L (> 70 g/L) and he has no active cardiac ischemia.
2. Pre-Endoscopy Medical Therapy: Pantoprazole 80 mg IV bolus administered, followed by 8 mg/hour IV infusion. Erythromycin 250 mg IV infused 45 minutes prior to endoscopy.
3. Endoscopic Findings: EGD reveals a 1.5 cm ulcer on the posterior duodenal bulb with a visible, non-bleeding vessel (Forrest IIa). Endoscopic hemostasis is successfully achieved using dual therapy: hemoclip application plus bipolar electrocoagulation. Biopsy for rapid urease testing (CLO test) is positive for H. pylori.
4. Post-Endoscopy Regimen: The high-dose IV pantoprazole infusion is continued for 72 hours, then transitioned to oral pantoprazole 40 mg BID.

Outpatient Discharge & Eradication Plan:

• H. pylori Eradication Prescription: Discontinue ibuprofen. In accordance with the Toronto Consensus, initiate 14-day Bismuth Quadruple Therapy:
  • Pantoprazole 40 mg PO BID (30 min before breakfast and dinner)
  • Bismuth subsalicylate 524 mg PO QID (with meals and bedtime)
  • Metronidazole 500 mg PO TID (with meals)
  • Tetracycline 500 mg PO QID (on an empty stomach, 1 hour before or 2 hours after meals, separated from dairy/calcium)
• Patient Counseling: Explain harmless blackening of stools and tongue, strictly proscribe alcohol intake while on metronidazole, and warn against concurrent dairy or antacids with tetracycline.
• Mandatory Follow-Up: Schedule a Urea Breath Test at 6 weeks (ensuring at least 4 weeks have elapsed since completing antibiotics and at least 2 weeks since stopping his maintenance PPI) to definitively confirm H. pylori eradication.